The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Objective response rate and progression-free survival as surrogate endpoints for overall survival and the impact of crossover and unbalanced post-progression treatments: A systematic review and meta-analysis in first-line therapy of advanced non-small cell lung cancer.
 
Boris Pfeiffer
Employment - Merck KGaA
 
Mahmoud Hashim
Consulting or Advisory Role - Janssen (Inst); Merck KGaA (Inst); Teva (Inst)
Research Funding - Janssen (Inst); Merck KGaA (Inst); Teva (Inst)
 
Monica Duran
Research Funding - Merck KGaA (Inst); Teva (Inst)
 
Maarten Postma
Honoraria - Idem Healthcare
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Intercept Pharmaceuticals; Janssen; MSD; Novartis; Pfizer; Quintiles; Sanofi; Sanofi Pasteur; Sigma-Tau; Vertex
Research Funding - Idem Healthcare (Inst)
 
Bart Heeg
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Merck KGaA (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Merck KGaA (Inst); Pfizer (Inst); Sanofi (Inst)